Intensely Pruritic Rash After Sun Exposure in a Tween Girl

Poll

What are the characteristics of this blistering rash caused by exposure to UV light?


This intensely itchy, blistering rash on the forearms and upper chest of a 13-year-old girl occurred after a day at the beach. The girl had polymorphic light eruption (PMLE), the most common abnormal reaction to UV light.

All of the following statements about PMLE are true, except:

A. PMLE classically presents as a papular or papulovesicular eruption on the arms and anterior chest
B. The reaction usually begins 12 to 24 hours after an initial exposure to light of a suddenly increased intensity
C. Some parts of the body are severely involved while similarly exposed areas are paradoxically spared
D. The rash resolves after 7 to 10 days, often leaving whitish scarring
Related Content
Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Grace Halsey
January 10th 2025
Article

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose / image credit: ©New Africa/AdobeStock

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose

Sydney Jennings
January 8th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose

Sydney Jennings
January 6th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years / image credit DOCS Dermatology Rocco Serrao, MD

FDA Receives sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Grace Halsey
December 16th 2024
Article

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis / Image credit: ©Argus/AdobeStock

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis

Sydney Jennings
December 16th 2024
Article

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older / image credit ©Waldenmarus/stock.adobe.com

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older

Grace Halsey
December 16th 2024
Article

Approval for the topical nonsteroidal therapy, based on data from the phase 3 ADORING clinical trial program, helps fill a gap in current offerings for atopic dermatitis.

© 2025 MJH Life Sciences

All rights reserved.